Clinical Trial Search

Primary: Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal…

Primary: Number of Participants Who Have Not Used Tobacco in the Past 30 Days — 18; 26; 10 Participants

Primary: Time to a Protocol-defined Pulmonary Exacerbation — 1.350; 0.758 years — p=0.0043

Primary: Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound — 38.7; 35.0 percentage of participants

Primary: Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score — -20.32; -20.72; -22.71 units on a scale — p=0.7662

Primary: Invasive Disease-free Survival (IDFS) Rate at 3 Years — 77.12; 88.44 percentage of participants — p=<0.0001

Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26

Primary: 30-day Abstinence — 168; 237; 302 Participants

Primary: Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria — NA; NA months — p=<0.0001

Primary: Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48 — 84.5; 70.0 Percentage of participants — p=<0.001

Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001

Primary: SleepSure (Questionnaire). A Short Questionnaire of the Quality and Quantity of Sleep, and Use of Aids. — 5.09; 6.33 units on a scale

Primary: Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12 — -12.25; -12.09; -7.91 days/month — p=0.0001

Primary: ADP-induced Inhibition of Platelet Aggregation — 54.9; 80.6; 73.6; 66 percentage of inhibition of platelet agg

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis — -20.3; -56.0 percent change — p=<0.0001